1cP-MiPLA

1cP-MiPLA (1-cyclopropanoyl-MiPLA) is a synthetic psychedelic of the lysergamide family and the N1-cyclopropanoyl ester of MiPLA (N-methyl-N-isopropyl lysergamide). By structural analogy with other 1-acyl lysergamide prodrugs such as 1cP-LSD, 1cP-MiPLA is believed to function as a prodrug for MiPLA, with esterase-mediated cleavage of the cyclopropanoyl group releasing the pharmacologically active MiPLA following ingestion.

MiPLA itself is an unusual lysergamide featuring N,N-methyl-isopropyl amide substitution rather than the diethyl amide group of LSD, producing a somewhat shorter-acting and reportedly more clarity-oriented psychedelic experience. Community experience with 1cP-MiPLA, while limited compared to more widely used analogs, describes an experience that is noticeably shorter than LSD (4–7 hours), somewhat more introspective and mentally clear, and less visually overwhelming. This character has made it of interest to users who find LSD's long duration difficult to manage.

1cP-MiPLA is among the less well-documented lysergamide research chemicals. Very few formal experience reports exist, and its pharmacology has not been directly studied in humans. Users are essentially treating it as a proxy for MiPLA, applying the prodrug logic that has been confirmed for 1cP-LSD and inferred for other 1-acyl compounds. This means that dosing, duration, and effects are substantially uncertain, and extreme caution with initial doses is warranted.

As with all research chemical lysergamides, testing with Ehrlich reagent is essential before use, and those with personal or family history of psychosis should not use this compound. The overall risk profile is assumed to parallel other lysergamide prodrugs but has not been formally characterized.